Improvement of glycemic state among responders to Sofosbuvir‐based treatment regimens: Single center experience

Abstract

Chronic HCV infection has emerged as a complex multifaceted disease with manifestations extending beyond the liver. HCV plays a direct role in glucose metabolism leading to both insulin resistance and type 2 diabetes. To evaluate the changes in the glycemic state following Sofosbuvir-based treatment regimens in diabetic HCV patients. Four hundred chronic hepatitis C patients who underwent Sofosbuvir-based treatment regimens were retrospectively screened. Sixty-five diabetic HCV patients only enrolled in our analysis. Baseline demographic and laboratory data were recorded. Pretreatment Transient elastography was performed. At 24-week post EOT (SVR24), Fasting Plasma glucose, and Hemoglobin A1c were re-evaluated and compared with baseline. All enrolled diabetic patients were responders. They showed statistically significant decline in Fasting Plasma glucose and Hemoglobin A1c values at SVR24. Whatever the degree of hepatic fibrosis, the level of Fasting Plasma glucose and Hemoglobin A1c decreased at SVR24 in comparison to baseline level. Fifty-one patients showed improvement in their Hemoglobin A1c values at SVR24 and this improvement was more likely to occur among patients with low Body mass index. The reduction in Fasting Plasma glucose >20 mg/dL (>1.1 mmol/L) and Hemoglobin A1c ≥0.5% was not associated with age, gender or hepatic fibrosis stage. Sofosbuvir-based regimens are a highly efficient antiviral therapy for diabetic chronic HCV patients resulted in improvement in Fasting Plasma glucose and Hemoglobin A1c.

Hepatitis C virus eradication with direct‐acting antiviral improves insulin resistance

“…After the widespread adoption of highly effective direct‐acting antivirals (DAAs), preliminary data from case series and cohort studies confirmed what previously described in the IFN era . However, most of them were mono‐centric and/or retrospective, with a relatively short duration of follow‐up.…”

Benchmarks of Diabetes Care in Men Living With Treated HIV-Infection: A Tertiary Center Experience

“…HCV co-infection is associated with peripheral insulin resistance and poor glucose control in diabetes (44). Current pharmacotherapy for HCV using Sofosbuvir and Velpatasvir as shown high rates of virus eradication (45) and improved glucose control (46, 47). Therefore, people with HCV co-infection should be offered access to HCV eradication.…”

Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

“…Clearance of HCV infection with DAA therapy can improve hepatic function and thereby affect the safety and efficacy of some concomitantly administered medications. Real‐world data indicate an association between DAA therapy and reduced glycemia, particularly among people with diabetes . Patients taking diabetes medication(s) should be informed of the potential for symptomatic hypoglycemia during and after DAA therapy.…”